UCB S.A.
UCB
Rangering i aksjer
#525
UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in... UCB S.A., a biopharmaceutical enterprise founded in 1925 and headquartered in Brussels, Belgium, focuses on developing innovative solutions for individuals living with neurological and immunological diseases. Its diverse commercialized portfolio includes Cimzia, targeting inflammatory TNF-mediated conditions such as Crohn's disease, various forms of spondyloarthritis, rheumatoid arthritis, and psoriasis. For epilepsy management, UCB offers Vimpat, Keppra, and Briviact, along with Nayzilam, an intranasal rescue treatment for seizure clusters. Neupro is available for Parkinson's disease and restless legs syndrome, while Zyrtec and Xyzal address allergy symptoms. Other key products include Evenity for osteoporosis in postmenopausal women, and BIMZELX, which treats psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. The company also provides dapirolizumab pegol for systemic lupus erythematosus. UCB's robust development pipeline features candidates like rozanolixizumab, aimed at myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan for myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam for prolonged seizures; Bepranemab for Alzheimer's disease; and UCB0599 for Parkinson's disease. Beyond its proprietary drug development, UCB also conducts contract manufacturing. The company engages in significant collaborations with entities such as Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. UCB's global footprint extends across numerous countries, including the United States, Japan, China, Belgium, and a broad presence throughout Europe, encompassing Germany, Spain, France, Italy, the United Kingdom, and Ireland.
Aksjekurs
$242.33
Markedsverdi
$46.20B
Endring (1 dag)
-0.15%
Endring (1 år)
-16.40%
Land
BE
Handel UCB S.A. (UCB)
Kategori
Healthcare
Driftsmargin for UCB S.A. (UCB)
Driftsmargin per October 2026 TTM: 31.23%
Ifølge UCB S.A. sine siste økonomiske rapporter og aksjekurs er selskapets nåværende driftsmargin (TTM) 31.23%. Ved slutten av 2023 hadde selskapet en driftsmargin på 11.50%.
Historikk for driftsmargin for UCB S.A. fra 2002 til 2026
Driftsmargin ved slutten av hvert år
| År | Driftsmargin | Endre |
|---|---|---|
| 2026 (TTM) | 31.23% | 45.12% |
| 2024 | 21.52% | 87.13% |
| 2023 | 11.50% | 58.62% |
| 2022 | 7.25% | -63.48% |
| 2021 | 19.85% | 8.65% |
| 2020 | 18.27% | -17.18% |
| 2019 | 22.06% | -8.12% |
| 2018 | 24.01% | -0.08% |
| 2017 | 24.03% | 25.22% |
| 2016 | 19.19% | 28.88% |
| 2015 | 14.89% | 31.07% |
| 2014 | 11.36% | 16.27% |
| 2013 | 9.77% | -13.08% |
| 2012 | 11.24% | 6.04% |
| 2011 | 10.60% | 67.19% |
| 2010 | 6.34% | -76.40% |
| 2009 | 26.86% | 755.41% |
| 2008 | 3.14% | -66.91% |
| 2007 | 9.49% | -58.06% |
| 2006 | 22.63% | 45.53% |
| 2005 | 15.55% | 13.50% |
| 2004 | 13.70% | -6.29% |
| 2003 | 14.62% | 64.09% |
| 2002 | 8.91% | 0.00% |
Driftsmargin for lignende selskaper eller konkurrenter
| Selskap | Driftsmargin | Forskjell i driftsmargin | Land |
|---|---|---|---|
| 38.59% | -98.76% |
US
|
|
| -149.01% | -104.77% |
US
|
|
| 25.57% | -99.18% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.08% |
NL
|
Hva er selskapets Driftsmargin?
Driftsmargin er en nøkkelindikator for å vurdere lønnsomheten til et selskap. Høyere Driftsmargins er vanligvis bedre, da de viser at selskapet kan selge sine produkter eller tjenester for mye mer enn produksjonskostnadene. Driftsmargin beregnes ved å dele selskapets inntjening med inntektene.